The articles in this issue of NTR reflect the current major areas of nicotine/tobacco research: efficacy of treatment, special populations, and harm reduction. In terms of efficacy, most treatments that have focused on extinguishing smoking cues have not been effective; however, Brandon and colleagues1 used an innovative program to assist varenicline in disrupting cues and found that it reduced both craving and satisfaction from smoking. Ignacio and colleagues2 found that smokers with psychiatric or smoking-related illnesses were more likely to be offered pharmacotherapy for smoking cessation. Koslovsky and colleagues3 used a sophisticated statistical produce to replicate prior work4 that which variables predict relapse varies over time. Pacek and colleagues5 reviewed the literature on factors that influenced adherence to treatment and did not any factor that did so consistently; however, they also suggest several methodological changes that might reveal such factors. Prior research found that smokers with strokes in the insular region had higher short-term abstinence. Suner-Soler and colleagues6 replicated that result and found its effect appeared to be due to its influence on “disruption of addiction,” defined as smoking cessation from the moment of the stroke, the absence of relapses, and having stopped smoking without difficulties.